Results 131 to 140 of about 58,717 (264)

Overlap of Obstructive Sleep Apnea (OSA) and Hypoventilation Syndrome in the context of advanced kyphoscoliosis

Tarcísio Nunes Alvarenga, José Eduardo Trentim Longo, Bianca Latance da Cruz, Gabriela Rossini Dantas, Itamar Meireles Andrade Santos, Jeronimo Moda, Luís M. Silva, Maria Clara Foloni, Rebeca Aranha Barbosa Sousa, Camila Bonfanti Baima   +9 more
openalex   +1 more source

Comprehensive review of surgeries for obstructive sleep apnea syndrome

, 2013
Macario Camacho, Victor Certal, Robson Capasso   +2 more
openalex   +1 more source

Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Semaglutide, a GLP‐1 receptor agonist, has shown efficacy in promoting weight loss. However, limited data exist on its impact on lean mass, muscle function, and metabolic adaptations. The SEMALEAN study aims to evaluate these parameters in patients with obesity treated with Semaglutide (2.4 mg).
Mathieu Alissou, Thomas Demangeat, Vanessa Folope, Hélène Van Elslande, Hélène Lelandais, Julia Blanchemaison, Pierre‐Emmanuel Cailleaux, Suzan Guney, Alexandra Aupetit, Agnès Aubourg, Clément Rapp, André Petit, Morgane Godin, Luc Vignal, Sébastien Grigioni, Pierre Déchelotte, Guillaume Colange, Moïse Coëffier, Najate Achamrah   +18 more
wiley   +1 more source

Lack of Exercise is Associated With Psychological Distress in Patients With Obstructive Sleep Apnea Syndrome. [PDF]

Cureus
Kataoka H, Miyatake N.
europepmc   +1 more source

Sleep Bruxism Episodes in Patients with Obstructive Sleep Apnea Syndrome Determined by In-Laboratory Polysomnography [PDF]

, 2020
Dong‐Hyun Kim, Sang Hwa Lee, Sang Haak Lee   +2 more
openalex   +1 more source

Relative efficacy of GLP‐1 and GLP‐1/GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims There is growing evidence that the GLP‐1 system is implicated in alcohol and other substance use disorders, and that GLP‐1‐based therapies may have therapeutic relevance in alcohol use disorder (AUD). We aimed to determine the impact of GLP‐1 based therapies on incident AUDs in a real‐world setting in patients with T2D.
Alex E. Henney, David R. Riley, Megan Heague, Carl A. Roberts, Theresa J. Hydes, Matthew Anson, David M. Hughes, Uazman Alam, Daniel J. Cuthbertson   +8 more
wiley   +1 more source

An Insight into the Formulation of the Iraqi Version of the Pediatric Sleep Questionnaire for Children with Obstructive Sleep Apnea Syndrome [PDF]

MahmoodDhahir Al-Mendalawi
openalex   +1 more source

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Evaluation of inflammatory markers in obstructive sleep apnea syndrome. [PDF]

Sci Prog
Ucar Y, Sahin A.
europepmc   +1 more source

Effectiveness and safety of GLP‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Acquired hypothalamic obesity (aHO) following craniopharyngioma (CP) is a challenging condition with limited therapeutic options. This study aimed to assess the real‐world effectiveness and safety of GLP‐1 RAs in this population. Materials and Methods CranioGLP1 is a retrospective multicentre study including 116 adults with aHO treated ...
Flora Lambert, Emilie Guillon, Blandine Gatta‐Cherifi, CranioGLP1_FORCE Group, Flora Lambert, Emilie Guillon, Hedi Soula, Christine Poitou, Pauline Faucher, Frédérique Albarel, Jean‐Baptiste Bonnet, Anne‐Laure Borel, Marie‐Claude Brindisi, Claire Carette, Delphine Drui, Cédric Fagour, Nicolas Farigon, Bénédicte Gaborit, Blandine Gatta‐Cherifi, Fréderic Illouz, Ryme Jouini‐Bouhamri, Ibrahima Maiga, Emilie Montastier, Héléna Mosbah, Géraldine Vitellius, Olivier Ziegler, Hedi Soula, Christine Poitou, Pauline Faucher   +28 more
wiley   +1 more source